In this US nationwide cohort study assessing the risk of AF among more than 200 000 Medicare beneficiaries with type 2 diabetes, after propensity score matching, the initiation of SGLT-2is was associated with an 18% decrease in the risk of AF compared with dipeptidyl peptidase-4 inhibitors and a 10% decrease in the risk of AF compared with glucagon-like peptide-1 receptor agonists. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.